Additionally, some patients may have access to generic or biosimilar versions of GLP-1 medications, which can be more affordable
Eli Lilly and Company Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
JavaScript is disabled In order to continue, we need to verify that you're not a robot
How This Pack Solves Problems: GLP-1 therapy can be life-changing, but the side effects shouldnt stand in the way of your success
Improved Health Markers: Beyond weight loss, many patients see improvements in other health areas, such as lower blood sugar levels, better blood pressure, and healthier cholesterol numbers